Memantina Stada (Memantine Hydrochloride)

Memantina Stada is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders.

• Moderate to severe Alzheimer’s disease: improves cognition and daily functioning.
• Mild‑to‑moderate Alzheimer’s disease (off‑label): may provide modest cognitive benefit.
• Behavioral disturbances in Alzheimer’s disease: may reduce agitation and aggression.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by overstimulation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory.

Memantina Stada may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements, manageable with diet.
• Confusion: occasional disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Seizures: rare occurrence, monitor patients with seizure history.
• Hepatic failure: signs of liver dysfunction.
• Cardiac arrhythmia: irregular heartbeat.
• Suicidal thoughts: emergent psychiatric symptoms.
• Severe allergic reaction: anaphylaxis, airway compromise.

Before initiating Memantina Stada, clinicians should consider several safety factors.

• Renal impairment: dose adjustment may be required.
• History of seizures: monitor closely for breakthrough events.
• Cardiovascular disease: observe blood pressure and heart rate.
• Concurrent use with other NMDA antagonists: avoid combined therapy.
• Pregnancy: safety unknown; use only if benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Stada can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Other NMDA antagonists (e.g., ketamine): combined effect can lead to excessive blockade.
• Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effects.
• Antihypertensive agents: additive blood‑pressure lowering.
• Anticholinergic drugs: may diminish cognitive benefit of memantine.